CLINICAL STAGE III GASTRIC CANCER AJCC V8
Clinical trials for CLINICAL STAGE III GASTRIC CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE III GASTRIC CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE III GASTRIC CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat cancers: drug targets DNA repair weakness
Disease control OngoingThis phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …
Matched conditions: CLINICAL STAGE III GASTRIC CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests an experimental drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially urothelial cancer. The goal is to find the best dose and see how safe the combination…
Matched conditions: CLINICAL STAGE III GASTRIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat stomach cancer
Disease control OngoingThis phase 2 trial tested a combination of two drugs, berzosertib and irinotecan, in 17 patients with advanced stomach or gastroesophageal junction cancer that has a specific genetic change (TP53 mutation) and was getting worse. The goal was to see if the combination could shrink…
Matched conditions: CLINICAL STAGE III GASTRIC CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New drug cocktail aims to shrink advanced stomach tumors
Disease control OngoingThis early-phase trial is testing whether combining two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and lenvatinib (which blocks enzymes that help tumors grow)—can shrink tumors in people with advanced stomach or gastroesophageal cancer that …
Matched conditions: CLINICAL STAGE III GASTRIC CANCER AJCC V8
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Shorter radiation before stomach cancer surgery shows promise in early trial
Disease control OngoingThis early-phase trial tests whether a shorter course (2 weeks instead of 5) of chemoradiotherapy before standard chemotherapy and surgery is safe and effective for people with resectable stomach cancer. About 25 participants will receive the shortened radiation combined with che…
Matched conditions: CLINICAL STAGE III GASTRIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Experimental drug combo targets Hard-to-Treat GI cancers
Disease control OngoingThis trial tests a new drug called BAY 1895344 (elimusertib) combined with standard chemotherapy (FOLFIRI) in people with advanced or metastatic stomach or colorectal cancer. The goal is to find the safest dose and see if the combination can shrink tumors. Participants receive th…
Matched conditions: CLINICAL STAGE III GASTRIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New combo therapy targets Hard-to-Treat stomach cancers in Mid-Stage trial
Disease control OngoingThis phase II trial is testing whether adding chemotherapy to the immunotherapy drug atezolizumab works better than atezolizumab alone for patients with a specific genetic type of stomach or gastroesophageal junction cancer (MSI-H/dMMR). The study involves 240 adults with localiz…
Matched conditions: CLINICAL STAGE III GASTRIC CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Experimental combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…
Matched conditions: CLINICAL STAGE III GASTRIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests two drugs together—sonidegib and pembrolizumab—in 36 adults with advanced solid tumors that have spread. Sonidegib blocks a growth signal in cancer cells, while pembrolizumab helps the immune system attack the tumor. The main goals are to find the saf…
Matched conditions: CLINICAL STAGE III GASTRIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Heated chemo during surgery may stop stomach Cancer's return
Prevention ENROLLING_BY_INVITATIONThis study tests whether giving heated chemotherapy directly into the abdomen during surgery can prevent stomach or gastroesophageal junction cancer from returning in the abdominal lining. The treatment uses drugs cisplatin and paclitaxel, which are heated and circulated in the b…
Matched conditions: CLINICAL STAGE III GASTRIC CANCER AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Prevention
Last updated Jul 03, 2026 00:00 UTC
-
New recovery protocol aims to get stomach cancer patients home sooner
Symptom relief OngoingThis phase II trial tests an enhanced recovery after surgery (ERAS) protocol in 52 people with stage 0 to IIIC gastric cancer who are having surgery. The goal is to see if this approach can reduce pain, nausea, and hospital stays while improving quality of life. Participants rece…
Matched conditions: CLINICAL STAGE III GASTRIC CANCER AJCC V8
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC